deaths (OS)

metastatic, hormone-sensitive prostate cancer metastatic, hormone-sensitive prostate cancer

versus androgen deprivation therapy (ADT)
enzalutamide plus ADT vs. androgen deprivation therapy (ADT) 2 certainty unassessable-31%